Decompensated cirrhotic patients treated with entecavir without virologic response faced risk for HCC

Patients with decompensated cirrhosis who did not achieve virologic response with entecavir treatment were still at risk for hepatocellular carcinoma, compared with compensated patients, according to data from a new study.

Researchers studied 306 patients (mean age, 49.4 years; 68.3% men) with chronic hepatitis B and cirrhosis between December 2006 and September 2011. Each patient was assigned 0.5 mg entecavir (ETV) every 3 to 6 months for at least 12 months at a South Korean hospital. Median follow-up was 37 months.

Compensated cirrhosis was diagnosed in 68.3% of patients, 31.7% had decompensated cirrhosis, and 17% previously had received antiviral treatment before ETV.


Labels: , , ,